MX2018011306A - Vector multimodal para infeccion de celulas dentriticas. - Google Patents
Vector multimodal para infeccion de celulas dentriticas.Info
- Publication number
- MX2018011306A MX2018011306A MX2018011306A MX2018011306A MX2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- antigens
- cancer
- dendritic cell
- specific
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 abstract 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 102100022339 Integrin alpha-L Human genes 0.000 abstract 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1777—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310551P | 2016-03-18 | 2016-03-18 | |
| US201662313596P | 2016-03-25 | 2016-03-25 | |
| PCT/US2017/023117 WO2017161360A2 (en) | 2016-03-18 | 2017-03-20 | Multimodal vector for dendritic cell infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011306A true MX2018011306A (es) | 2019-08-16 |
Family
ID=59850551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011306A MX2018011306A (es) | 2016-03-18 | 2017-03-20 | Vector multimodal para infeccion de celulas dentriticas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210198689A1 (OSRAM) |
| EP (1) | EP3430148A4 (OSRAM) |
| JP (1) | JP2019508044A (OSRAM) |
| KR (1) | KR20180118198A (OSRAM) |
| CN (1) | CN109312364A (OSRAM) |
| AU (1) | AU2017233072B2 (OSRAM) |
| CA (1) | CA3016389A1 (OSRAM) |
| IL (1) | IL261812A (OSRAM) |
| MX (1) | MX2018011306A (OSRAM) |
| SG (1) | SG11201808058PA (OSRAM) |
| WO (1) | WO2017161360A2 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201414021D0 (en) | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| CN108351917B (zh) | 2015-08-25 | 2022-03-08 | 南托米克斯有限责任公司 | 用于高精度识别变体的系统和方法 |
| MY193281A (en) | 2015-12-17 | 2022-09-30 | Psioxus Therapeutics Ltd | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
| SG11201811074RA (en) | 2016-06-30 | 2019-01-30 | Nant Holdings Ip Llc | Nant cancer vaccine |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| KR102427563B1 (ko) | 2016-08-29 | 2022-08-03 | 싸이오서스 테라퓨틱스 엘티디. | 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스 |
| CN118308311A (zh) | 2017-06-01 | 2024-07-09 | 阿卡米斯生物公司 | 溶瘤病毒和方法 |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2678259C (en) * | 1998-12-09 | 2016-10-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| WO2002080851A2 (en) * | 2001-04-05 | 2002-10-17 | The Johns Hopkins University | Chimeric vaccines |
| EP1441759A2 (de) * | 2001-11-09 | 2004-08-04 | MediGene Aktiengesellschaft | Zelluläre impfstoffe mit adjuvanzien |
| US20040156828A1 (en) * | 2003-01-07 | 2004-08-12 | Ruian Xu | Adeno-associated virus mediated B7.1 vaccination synergizes with angiostatin to eradicate disseminated liver metastatic cancers |
| US8562970B2 (en) * | 2003-10-08 | 2013-10-22 | Sanofi Pasteur Limited | Modified CEA/B7 vector |
| EP1874348A4 (en) * | 2005-04-14 | 2009-10-28 | Univ Queensland | IMMUNOREGULATORY COMPOSITIONS AND THEIR USE |
| WO2012038606A1 (en) * | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| CA2847057C (en) * | 2011-08-31 | 2019-06-11 | St. Jude Children's Research Hospital | Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use |
| CN102533859A (zh) * | 2012-01-12 | 2012-07-04 | 中国人民解放军第二军医大学 | 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用 |
| US9657076B2 (en) * | 2012-10-23 | 2017-05-23 | Emory University | GM-CSF and IL-4 conjugates, compositions, and methods related thereto |
| MY182168A (en) * | 2013-11-01 | 2021-01-18 | Pfizer | Vectors for expression of prostate-associated antigens |
| KR20160070095A (ko) * | 2013-11-05 | 2016-06-17 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제 |
| EP3082853A2 (en) * | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| US11028143B2 (en) * | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| EP3142690B1 (en) * | 2014-05-13 | 2022-02-23 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
-
2017
- 2017-03-20 KR KR1020187028404A patent/KR20180118198A/ko not_active Ceased
- 2017-03-20 MX MX2018011306A patent/MX2018011306A/es unknown
- 2017-03-20 CA CA3016389A patent/CA3016389A1/en not_active Abandoned
- 2017-03-20 EP EP17767693.9A patent/EP3430148A4/en not_active Withdrawn
- 2017-03-20 CN CN201780017523.9A patent/CN109312364A/zh active Pending
- 2017-03-20 SG SG11201808058PA patent/SG11201808058PA/en unknown
- 2017-03-20 AU AU2017233072A patent/AU2017233072B2/en not_active Ceased
- 2017-03-20 US US16/081,014 patent/US20210198689A1/en not_active Abandoned
- 2017-03-20 JP JP2018546653A patent/JP2019508044A/ja active Pending
- 2017-03-20 WO PCT/US2017/023117 patent/WO2017161360A2/en not_active Ceased
-
2018
- 2018-09-16 IL IL261812A patent/IL261812A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180118198A (ko) | 2018-10-30 |
| SG11201808058PA (en) | 2018-10-30 |
| AU2017233072B2 (en) | 2020-12-24 |
| IL261812A (en) | 2018-10-31 |
| WO2017161360A4 (en) | 2017-11-16 |
| EP3430148A2 (en) | 2019-01-23 |
| EP3430148A4 (en) | 2020-01-01 |
| JP2019508044A (ja) | 2019-03-28 |
| WO2017161360A3 (en) | 2017-10-26 |
| WO2017161360A2 (en) | 2017-09-21 |
| CN109312364A (zh) | 2019-02-05 |
| US20210198689A1 (en) | 2021-07-01 |
| CA3016389A1 (en) | 2017-09-21 |
| AU2017233072A1 (en) | 2018-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011306A (es) | Vector multimodal para infeccion de celulas dentriticas. | |
| CY1122571T1 (el) | Μακροκυκλικοι αναστολεις των αλληλεπιδρασεων πρωτεϊνων/πρωτεϊνων ρd-1/ρd-l1 και cd80(β7-1)/ρd-l1 | |
| UY37194A (es) | Inmunomoduladores | |
| BR112017003718A2 (pt) | inibidores macrocíclicos das interações de proteína/proteína de pd-1/pd-l1 e cd80(b7-1)/pd-l1 | |
| MX2020003526A (es) | Una plataforma universal para la preparación de un receptor antigénico quimérico inhibidor (icar). | |
| MX373460B (es) | Metodo para generar celulas t compatibles para el trasplante alogenico. | |
| MX2025009055A (es) | Vectores de neoantigeno de alfavirus | |
| PH12019501130A1 (en) | Viral delivery of neoantigens | |
| MX2017010129A (es) | Inmunomoduladores. | |
| BR112017012704A2 (pt) | imunomoduladores | |
| MX379487B (es) | Inmunomoduladores. | |
| CL2017000855A1 (es) | Inmunomoduladores | |
| MX384422B (es) | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras | |
| MX2017007677A (es) | Inmunomoduladores. | |
| EA201791739A1 (ru) | Иммуномодуляторы | |
| UY36400A (es) | Péptidos macrocíclicos como inhibidores de las interacciones entre las proteínas pd-1/pd-l1 y cd80/pd-l1 y sus funciones inmunomoduladoras | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| CO2019009815A2 (es) | Combinaciones farmacéuticas | |
| PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
| MX391149B (es) | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. | |
| CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
| BR112017006680A2 (pt) | variantes de vírus influenza a | |
| AR113124A1 (es) | Sistema de expresión de paramyxoviridae | |
| UY35733A (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c. | |
| MX2020013551A (es) | Combinaciones farmaceuticas. |